Citalopram and clarithromycin — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Additive QT prolongation and arrhythmia risk
This scenario assesses Citalopram and clarithromycin in a UK pharmacy practice context. Citalopram and clarithromycin can both prolong QT interval, especially in older patients or with prior QT prolongation. The best answer is Additive QT prolongation and arrhythmia risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: BNF